GHUCCTS

News

Share This
  • June 15, 2020

NIH announces RADx-UP initiative to improve COVID-19 testing for underserved and vulnerable populations

The National Institutes of Health (NIH) has launched an unprecedented four-pronged initiative, entitled Rapid Acceleration of Diagnostics, or RADx, to catalyze the scientific community to improve testing technologies, capacity, and accessibility for the country. As one of the four RADx components, RADx-Underserved Populations (RADx-UP) will establish a network of community-engaged projects to improve access to and acceptance of testing in underserved and vulnerable populations. The overarching goal of this $500M effort is to understand factors that have led to disproportionate burden of the pandemic on these populations, so that interventions can be implemented to decrease the disparities.

As part of the RADx-UP initiative, NIH has released four funding opportunities to solicit community-engaged research on COVID-19 testing among underserved and/or vulnerable populations to both understand and close the disparity gap. These funding opportunities include:

  1. Emergency competitive revision applications to existing awards for large consortia, multi-site trials, centers and other current networks that have adequate capacity, infrastructure, and established community-engaged relationships to support large-scale testing interventions or have the capacity to ramp up quickly to reach underserved or vulnerable populations. (NOT-OD-20-121)

  2. Complementary emergency competitive revision opportunity which shifts eligibility to collaborative and individual research awards, generally focused on smaller underserved or vulnerable populations. (NOT-OD-20-120)

  3. Emergency competitive revisions to solicit research to understand the social, ethical, and behavioral implications (SEBI) of COVID-19 testing in these populations. (NOT-OD-20-119)

  4. A new Coordination and Data Collection Center (CDCC) award (U24), a key component of the consortium. The CDCC will serve as a national resource, working with NIH scientific staff and consortium members to provide overarching support and guidance in the following four domains: (1) Administrative Operations and Logistics, (2) COVID-19 Testing Technology, (3) Community and Health System Engagement and (4) Data Collection, Integration and Sharing. (RFA-OD-20-013)

Applications for this first phase will be accepted through August 2020. A second phase will be staggered to provide flexibility and to allow for adaption to the ever-changing needs that may be present as this pandemic evolves. 

Please email ghuccts@georgetown.edu if you are interested in collaborating on an application for these awards.

Related News

GHUCCTS announces 2020 KL2 Scholar Dr. Haiyan He

Nov 13, 2020

After our 10th highly competitive application cycle, unfortunately delayed due to COVID-related research closures, the Georgetown-Howard Universities Center for Clinical and Translational Science (GHUCCTS) is pleased to announce the appointment of Dr. Haiyan He as a KL2 Scholar. This new awardee, her research project, and training plan are emblematic of our program objectives in that they pair a highly-promising scholar-trainee with a mentor team that includes senior colleagues from across disciplines, departments, campuses, and institutions to pursue research that depends upon collaborations and methods from outside the scholars’ discipline, local research environment, or past experiences.

Application open for 2021 KL2 Scholars Program

Nov 13, 2020

The Georgetown-Howard Universities Center for Clinical and Translational Science (GHUCCTS) is now accepting applications for our 2021 KL2 Scholars Program. The pre-application is due December 31, 2020 with the final application due February 1, 2021. Funding is expected to begin in June 2021 pending the evolution of the COVID-19 pandemic.

ACTS now accepting session proposals and abstracts for TS21

Nov 01, 2020

The Association for Clinical and Translational Science (ACTS) is now accepting session proposals and abstracts for Translational Science 2021.

Close